Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — J.P. Morgan Healthcare Conference 2018
17 slides from Emergent Biosolutions's conference presentation, Jan 8, 2018
Slide 1: Corporate Update, J.P. Morgan Healthcare Conference
Slide 2: Safe-Harbor Statement
Safe-Harbor StatementThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial projections, and any other statements containi
Slide 3: Our mission is simple – To Protect and Enhance Life
Our mission is simple – To Protect and Enhance Life As a global specialty life sciences company, Emergent is focused on providing specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats
Slide 4: Public Health Threats: Diverse and Growing Global Threat Landscape
C B R N E CHEMICAL: Nerve agents, cyanide, chlorine, toxic industrial chemicalsBIOLOGICAL: Anthrax, smallpox, botulism, Ebola, other category A threats RADIOLOGICAL/NUCLEAR: Nuclear, radiological agentsEXPLOSIVE: Trauma, burn, wound care E I D EMERGING INFECTIOUS DISEASES: Pandemic influenza, Zika,
Slide 5: History of Solid Business & Financial Growth
>10Pipeline Products Revenue Growth ($ Millions) 2012-2017 History of Solid Business & Financial Growth 13GLOBAL LOCATIONS 8MARKETEDPRODUCTS 4 PLATFORMSHyperimmunes Auto-injector AntiviralsAntibacterials SERVICESDevelopment & CMO SERVICES (Bulk Manufacturing Aseptic Fill/Finish) At a Glance Net Inco
Slide 6: Growing, Well-Funded PHT Market
Maturing International MarketRisk posed by state and non-state actorsEC Directive and EU Joint Procurement Mechanism, NATO Supply Agreement GlobalizationRapid disease transmission (Pandemic Flu, Ebola, Zika)Antimicrobial resistance Source: Health Security. 2016 Sep-Oct; 14(5): 284-304 US Government
Slide 7: Year-End 2020 Growth Plan Goals
Drivers:Accelerate organic growthComplete additional acquisitionsExpand service offerings TotalRevenue TargetedDevelopment Net IncomeMargin $ $1B>10% ex-US 6 Products In Advanced Development; 3 Dual-Market >14%1~30% EBITDA Margin Drivers:Advance existing portfolioLeverage platforms & technologiesFoc
Slide 8: Roadmap to Achieving 2020 Growth Plan Goals
8 Aligned Business Unit Structure Contract Manufacturing Devices Vaccines &Anti-infectives Antibody Therapeutics Roadmap to Achieving 2020 Growth Plan Goals Executing on Our 2020 Growth Plan Each Business Unit Possesses: Focused Leadership TeamsTailored Strategies & PlansRevenue-Generating Products/
Slide 9: Expanding Our Leadership Position: Marketed Products
Expanding Our Leadership Position: Marketed Products VIGIVCNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) ACAM2000® [Smallpox (Vaccinia) Vaccine, Live] Smallpox RSDL® [Reactive Skin Decontamination Lotion Kit] TROBIGARDTM [Atropine Sulfate (2 mg)/Obidoxime chloride (220 mg)] Auto-inj
Slide 10: Developing Innovative Products: Current Pipeline
Developing Innovative Products: Current Pipeline *Target for First Subject Enrollment.**Granted Fast Track Designation in December 2017 by the U.S. Food and Drug Administration. Executing on Our 2020 Growth Plan Vaccines & Therapeutics Platform Threat Partner PRV Potential Pre Clinical CLINICAL PHAS
Slide 11: Current CMO Services Offering
Current CMO Services Offering Executing on Our 2020 Growth Plan Diverse & Flexible cGMP Bulk ManufacturingViral/Non-Viral Aseptic Fill/FinishMaster/Working Cell and Virus BanksEnd-to-End Custom ManufacturingProcess and Analytical DevelopmentStability Testing Government-Selected Solutions Provider: C
Slide 12: M&A as a Driver of Growth
Clinical-stage Candidates PlatformTechnologies ManufacturingCapabilities RevenueGenerators Track Record of Successful M&A 2012-2017 M&A as a Driver of Growth Near-Term Revenue Contributors Long-Term Revenue Contributors Revenue Generating/Accretive OpportunitiesDual-Market ProductsCommercial Product
Slide 13: 2017 Performance Continued Trajectory Toward 2020 Goals
Preliminary Unaudited Financial Results Note: 2017 preliminary financial results shown in this presentation are only effective as of January 8, 2018, the date it was originally provided. Please see the appendix for non-GAAP reconciliation tables. Completed two revenue-generating acquisitionsAdvanced
Slide 14: 2018 Outlook
Financial Note: The guidance in this presentation is only effective as of the date it is originally provided, January 8, 2018. Please see the appendix for non-GAAP reconciliation tables. Advance NuThraxTM to enable EUA 2018 filing Complete ACAM2000® deliveries; establish multi-year follow-on contrac
Slide 15: Key Takeaways: Positioned for Value Creation Through 2020 and Beyond
Growing global public health threat marketUniquely positioned with focused strategy, proven core competencies, and aligned business unit structure supporting market leadershipCommitment to domestic and international revenue growth and diversification, organically and through M&AAttractive pipeline d
Slide 16: Appendix: Reconciliation Tables
Corporate UpdateAppendixReconciliationTablesJanuary 9, 2018
Slide 17: Reconciliation Tables
Reconciliation of Net Income to Adjusted Net Income Reconciliation of Net Income to EBITDA OLD DATA Reconciliation Tables
Emergent BioSolutions — J.P. Morgan Healthcare Conference 2018 on 6ix